ENDRA Life Sciences Inc
NASDAQ:NDRA
ENDRA Life Sciences Inc
Total Current Assets
ENDRA Life Sciences Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
Total Current Assets
$1m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Current Assets
$8.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Total Current Assets
$6.7B
|
CAGR 3-Years
30%
|
CAGR 5-Years
17%
|
CAGR 10-Years
13%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Current Assets
$14.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Current Assets
$26B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Current Assets
$9.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
16%
|
|
ENDRA Life Sciences Inc
Glance View
ENDRA Life Sciences, Inc. develops medical imaging technology. The company is headquartered in Ann Arbor, Michigan and currently employs 22 full-time employees. The company went IPO on 2017-06-28. The firm has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and stage progression of non-alcoholic fatty liver disease (NAFLD), which untreated, can progress to Non-alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The firm's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
See Also
What is ENDRA Life Sciences Inc's Total Current Assets?
Total Current Assets
1m
USD
Based on the financial report for Sep 30, 2025, ENDRA Life Sciences Inc's Total Current Assets amounts to 1m USD.
What is ENDRA Life Sciences Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
-26%
Over the last year, the Total Current Assets growth was -79%. The average annual Total Current Assets growth rates for ENDRA Life Sciences Inc have been -55% over the past three years , -26% over the past five years .
